Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review

References (160)

1. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. PubMed CrossRef
2. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411. PubMed CrossRef
3. Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT_2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983–992. PubMed CrossRef
4. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. PubMed CrossRef
5. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. PubMed CrossRef
6. Bogenschutz MP, Forcehimes AA, Pommy JA, et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289–299. PubMed CrossRef
7. Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. 2021;18(1):534–543. PubMed CrossRef
8. Aday JS, Heifets BD, Pratscher SD, et al. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl). 2022;239(6):1989–2010. PubMed CrossRef
9. Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(ja):1133–1152. PubMed CrossRef
10. Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2020;4(2):568–572. PubMed CrossRef
11. Nayak S, Johnson MW. Psychedelics and psychotherapy. Pharmacopsychiatry. 2021;54(4):167–175. PubMed
12. Gukasyan N, Nayak SM. Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy. Transcult Psychiatry. 2021;59(5):652-664. PubMed
13. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
14. Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation. Q J Stud Alcohol. 1970;31(4):932–949. PubMed CrossRef
15. Savage C, Cabe OLM, Kurland AA, et al.. LSD-Assisted Psychotherapy in the Treatment of Severe Chronic Neurosis. Farmingdale, NY: Baywood Pub Co; 1973.
16. Ludwig A, Levine J, Stark L, et al. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969;126(1):59–69. PubMed CrossRef
17. Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study. J Nerv Ment Dis. 1970;150(2):111–118. PubMed CrossRef
18. Johnson FG. LSD in the treatment of alcoholism. Am J Psychiatry. 1969;126(4):481–487. PubMed CrossRef
19. Rhead J, Soskin R, Turek I. Psychedelic drug (DPT)-assisted psychotherapy with alcoholics: a controlled study. J Psychoactive Drugs. 1977;9(4):287–300. CrossRef
20. Kurland A, Savage C, Pahnke WN, et al. LSD in the treatment of alcoholics. Pharmacopsychiatry. 1971;4(02):83–94. CrossRef
21. Soskin RA. The use of LSD in time-limited psychotherapy. J Nerv Ment Dis. 1973;157(6):410–419. PubMed CrossRef
22. Haertzen CA. On the addiction research center inventory scores of former addicts receiving LSD and untreated schizophrenics. Psychol Rep. 1964;14(2):483–488. CrossRef
23. Isbell H, Logan CR. Studies on the diethylamide of lysergic acid (LSD-25), II: effects of chlorpromazine, azacyclonol, and reserpine on the intensity of the LSD-reaction. AMA Arch Neurol Psychiatry. 1957;77(4):350–358. PubMed CrossRef
24. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897–3902. PubMed CrossRef
25. Hollister LE, Degan RO, Schultz SD. An experimental approach to facilitation of psychotherapy by psychotomimetic drugs. J Ment Sci. 1962;108(452):99–100. PubMed CrossRef
26. Holze F, Vizeli P, Müller F, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45(3):462–471. PubMed CrossRef
27. Holze F, Duthaler U, Vizeli P, et al. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharmacol. 2019;85(7):1474–1483. PubMed CrossRef
28. Wittmann M, Carter O, Hasler F, et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol. 2007;21(1):50–64. PubMed CrossRef
29. Wackermann J, Wittmann M, Hasler F, et al. Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neurosci Lett. 2008;435(1):51–55. PubMed CrossRef
30. Preller KH, Herdener M, Pokorny T, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27(3):451–457. PubMed CrossRef
31. Kraehenmann R, Pokorny D, Aicher H, et al. LSD increases primary process thinking via serotonin 2A receptor activation. Front Pharmacol. 2017;8:814. PubMed CrossRef
32. Kraehenmann R, Pokorny D, Vollenweider L, et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology (Berl). 2017;234(13):2031–2046. PubMed CrossRef
33. Preller KH, Schilbach L, Pokorny T, et al. Role of the 5-HT_2A receptor in self-and other-initiated social interaction in lysergic acid diethylamide-induced states: a pharmacological fMRI study. J Neurosci. 2018;38(14):3603–3611. PubMed CrossRef
34. Preller KH, Burt JB, Ji JL, et al. Changes in global and thalamic brain connectivity in lsd-induced altered states of consciousness are attributable to the 5-HT2A receptor. Hunt LT, Behrens TE, eds. eLife. 2018;7:e35082.
35. Barrett FS, Preller KH, Herdener M, et al. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cerebral Cortex. 2018;28(11):3939–3950.
36. Preller KH, Razi A, Zeidman P, et al. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proc Natl Acad Sci U S A. 2019;116(7):2743–2748. PubMed CrossRef
37. Pokorny T, Duerler P, Seifritz E, et al. LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychol Med. 2020;50(13):2255–2264. PubMed CrossRef
38. Jaffe J, Dahlberg CC, Luria J, et al. Speech rhythms in patient monologues: the influence of LSD-25 and dextroamphetamine. Biol Psychiatry. 1972;4(3):243–246. PubMed
39. Jaffe J, Dahlberg CC, Luria J, et al. Effects of LSD-25 and dextroamphetamine on speech rhythms in psychotherapy dialogues. Biol Psychiatry. 1973;6(1):93–96. PubMed
40. Dahlberg CC, Jaffe J. The effects of LSD-25 and dextroamphetamine on the use of defensive language. J Clin Psychol. 1979;35(2):250–254. PubMed CrossRef
41. Natale M, Dahlberg CC, Jaffe J. The effect of psychotomimetics on therapist–patient matching of speech “rhythms”. J Commun Disord. 1979;12(1):45–52. PubMed CrossRef
42. Mueller F, Lenz C, Dolder PC, et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry. 2017;7(4):e1084. PubMed CrossRef
43. Dolder PC, Schmid Y, Müller F, et al. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41(11):2638–2646. PubMed CrossRef
44. Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology (Berl). 2017;234(9-10):1499–1510. PubMed CrossRef
45. Dolder PC, Grünblatt E, Müller F, et al. A single dose of LSD does not alter gene expression of the serotonin 2a receptor gene (HTR2A) or early growth response genes (EGR1-3) in healthy subjects. Front Pharmacol. 2017;8:423. PubMed CrossRef
46. Müller F, Lenz C, Dolder P, et al. Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. Acta Psychiatr Scand. 2017;136(6):648–657. PubMed CrossRef
47. Müller F, Dolder PC, Schmidt A, et al. Altered network hub connectivity after acute LSD administration. Neuroimage Clin. 2018;18:694–701. PubMed CrossRef
48. Schmidt A, Müller F, Lenz C, et al. Acute LSD effects on response inhibition neural networks. Psychol Med. 2018;48(9):1464–1473. PubMed CrossRef
49. Schmid Y, Enzler F, Gasser P, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78(8):544–553. PubMed CrossRef
50. Strajhar P, Schmid Y, Liakoni E, et al. Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J Neuroendocrinol. 2016;28(3):12374. PubMed CrossRef
51. Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology (Berl). 2018;235(2):535–545. PubMed CrossRef
52. Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans, I: neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994;51(2):85–97. PubMed CrossRef
53. Strassman RJ, Qualls CR, Uhlenhuth EH, et al. Dose-response study of N,N-dimethyltryptamine in humans, II: subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51(2):98–108. PubMed CrossRef
54. Riba J, Valle M, Urbano G, et al. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003;306(1):73–83. PubMed CrossRef
55. Riba J, Anderer P, Morte A, et al. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol. 2002;53(6):613–628. PubMed CrossRef
56. Riba J, Rodríguez-Fornells A, Barbanoj MJ. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology (Berl). 2002;165(1):18–28. PubMed CrossRef
57. Ludwig AM, Levine J. A controlled comparison of five brief treatment techniques employing LSD, hypnosis, and psychotherapy. Am J Psychother. 1965;19(3):417–435. PubMed CrossRef
58. Levine J, Ludwig AM. Alterations in consciousness produced by combinations of LSD, hypnosis and psychotherapy. Psychopharmacology (Berl). 1965;7(2):123–137. PubMed CrossRef
59. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655–663. PubMed CrossRef
60. Zeifman RJ, Palhano-Fontes F, Hallak J, et al. The impact of ayahuasca on suicidality: results from a randomized controlled trial. Front Pharmacol. 2019;10:1325. PubMed CrossRef
61. Galvão ACde M, de Almeida RN, Silva EADS, et al. Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front Psychiatry. 2018;9:185. PubMed CrossRef
62. de Almeida RN, GalvãoACde M, da Silva FS, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: Observation from a randomized controlled trial. Front Psychol. 2019;10:1234. PubMed CrossRef
63. Smigielski L, Kometer M, Scheidegger M, et al. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep. 2019;9(1):14914. PubMed CrossRef
64. Smigielski L, Scheidegger M, Kometer M, et al. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage. 2019;196:207–215. PubMed CrossRef
65. Yanakieva S, Polychroni N, Family N, et al. The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2019;236(4):1159–1170. PubMed CrossRef
66. Family N, Maillet EL, Williams LTJ, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology (Berl). 2020;237(3):841–853. PubMed CrossRef
67. Kometer M, Schmidt A, Bachmann R, et al. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012;72(11):898–906. PubMed CrossRef
68. Kometer M, Schmidt A, Jäncke L, et al. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. 2013;33(25):10544–10551. PubMed CrossRef
69. Kometer M, Pokorny T, Seifritz E, et al. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology (Berl). 2015;232(19):3663–3676. PubMed CrossRef
70. Pokorny T, Preller KH, Kraehenmann R, et al. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol. 2016;26(4):756–766. PubMed CrossRef
71. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218(4):649–665. PubMed CrossRef
72. Johnson MW, Sewell RA, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 2012;123(1-3):132–140. PubMed CrossRef
73. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry. 2005;38(6):301–311. PubMed CrossRef
74. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, et al. Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis. Neuropsychopharmacology. 2006;31(2):431–441. PubMed CrossRef
75. Heekeren K, Neukirch A, Daumann J, et al. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J Psychopharmacol. 2007;21(3):312–320. PubMed CrossRef
76. Heekeren K, Daumann J, Neukirch A, et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl). 2008;199(1):77–88. PubMed CrossRef
77. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d -methamphetamine in healthy volunteers. Psychopharmacology (Berl). 1999;142(1):41–50. PubMed CrossRef
78. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, et al. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol. 1998;9(7):561–566. PubMed CrossRef
79. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers: a double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999;20(6):565–581. PubMed CrossRef
80. Gouzoulis-Mayfrank E, Thelen B, Maier S, et al. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology. 2002;45(4):205–212. PubMed CrossRef
81. Kraehenmann R, Preller KH, Scheidegger M, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78(8):572–581. PubMed CrossRef
82. Grimm O, Kraehenmann R, Preller KH, et al. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol. 2018;28(6):691–700. PubMed CrossRef
83. Daumann J, Heekeren K, Neukirch A, et al. Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl). 2008;200(4):573–583. PubMed CrossRef
84. Daumann J, Wagner D, Heekeren K, et al. Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol. 2010;24(10):1515–1524. PubMed CrossRef
85. Carbonaro TM, Johnson MW, Hurwitz E, et al. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology (Berl). 2018;235(2):521–534. PubMed CrossRef
86. Barrett FS, Carbonaro TM, Hurwitz E, et al. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology (Berl). 2018;235(10):2915–2927. PubMed CrossRef
87. Bershad AK, Schepers ST, Bremmer MP, et al. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry. 2019;86(10):792–800. PubMed CrossRef
88. Bershad AK, Preller KH, Lee R, et al. Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5(4):461–467. PubMed CrossRef
89. Natale M, Kowitt M, Dahlberg CC, et al. Effect of psychotomimetics (LSD and dextroamphetamine) on the use of figurative language during psychoanalysis. J Consult Clin Psychol. 1978;46(6):1579–1580. PubMed CrossRef
90. Rosenberg DE, Isbell H, Miner EJ, et al. The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacology (Berl). 1964;5(3):217–227. PubMed CrossRef
91. Vollenweider FX, Vontobel P, Hell D, et al. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man–a PET study with [11C]raclopride. Neuropsychopharmacology. 1999;20(5):424–433. PubMed CrossRef
92. Netz B, Jonsson CO, Bergqvist S. Effects of lysergic acid diethylamide (LSD-25) on normal subjects in a schizophrenia-discriminating test battery. Scand J Psychol. 1963;4(1):143–148. CrossRef
93. Dolezal V, Hausner M. Comparative phenomenology of experimental mental alterations after application of LSD, benactyzine and phenmetrzine. Act Nerv Super (Praha). 1968;10(3):280–282. PubMed
94. Hasler F, Grimberg U, Benz MA, et al. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl). 2004;172(2):145–156. PubMed CrossRef
95. Carter OL, Burr DC, Pettigrew JD, et al. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005;17(10):1497–1508. PubMed CrossRef
96. Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–1740. PubMed CrossRef
97. Santos RG, Landeira-Fernandez J, Strassman RJ, et al. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol. 2007;112(3):507–513. PubMed CrossRef
98. Dos Santos RG, Valle M, Bouso JC, et al. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. J Clin Psychopharmacol. 2011;31(6):717–726. PubMed CrossRef
99. Alonso JF, Romero S, Mañanas MÀ, et al. Serotonergic psychedelics temporarily modify information transfer in humans. Int J Neuropsychopharmacol. 2015;18(8):pyv039. PubMed CrossRef
100. Carter OL, Pettigrew JD, Hasler F, et al. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology. 2005;30(6):1154–1162. PubMed CrossRef
101. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78. PubMed CrossRef
102. Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513–520. PubMed CrossRef
103. Valle M, Maqueda AE, Rabella M, et al. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol. 2016;26(7):1161–1175. PubMed CrossRef
104. Strassman RJ, Qualls CR, Berg LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry. 1996;39(9):784–795. PubMed CrossRef
105. Riba J, Romero S, Grasa E, et al. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl). 2006;186(1):93–98. PubMed CrossRef
106. Carhart-Harris RL, Leech R, Williams TM, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012;200(3):238–244. PubMed CrossRef
107. Vollenweider FX, Csomor PA, Knappe B, et al. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology. 2007;32(9):1876–1887. PubMed CrossRef
108. Quednow BB, Kometer M, Geyer MA, et al. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology. 2012;37(3):630–640. PubMed CrossRef
109. Kometer M, Cahn BR, Andel D, et al. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry. 2011;69(5):399–406. PubMed CrossRef
110. Dos Santos RG, Grasa E, Valle M, et al. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl). 2012;219(4):1039–1053. PubMed CrossRef
111. Soskin RA, Grof S, Richards WA. Low doses of dipropyltryptamine in psychotherapy. Arch Gen Psychiatry. 1973;28(6):817–821. PubMed CrossRef
112. Umbricht D, Vollenweider FX, Schmid L, et al. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2003;28(1):170–181. PubMed CrossRef
113. Riba J, Anderer P, Jané F, et al. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology. 2004;50(1):89–101. PubMed CrossRef
114. Tagliazucchi E, Roseman L, Kaelen M, et al. Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol. 2016;26(8):1043–1050. PubMed CrossRef
115. Speth J, Speth C, Kaelen M, et al. Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. J Psychopharmacol. 2016;30(4):344–353. PubMed CrossRef
116. Timmermann C, Spriggs MJ, Kaelen M, et al. LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. Neuropharmacology. 2018;142:251–262. PubMed CrossRef
117. Bravermanová A, Viktorinová M, Tylš F, et al. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology (Berl). 2018;235(2):491–503. PubMed CrossRef
118. Barbanoj MJ, Riba J, Clos S, et al. Daytime ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology (Berl). 2008;196(2):315–326. PubMed CrossRef
119. Preller KH, Duerler P, Burt JB, et al. Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry. 2020;88(2):197–207. PubMed CrossRef
120. Preller KH, Pokorny T, Hock A, et al. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci U S A. 2016;113(18):5119–5124. PubMed CrossRef
121. Smart RG, Storm T, Baker EF, et al. A controlled study of lysergide in the treatment of alcoholism, 1: the effects on drinking behavior. Q J Stud Alcohol. 1966;27(3):469–482. PubMed CrossRef
122. Bernasconi F, Schmidt A, Pokorny T, et al. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cerebral Cortex. 2014;24(12):3221–3231.
123. Zegans LS, Pollard JC, Brown D. The effects of LSD-25 on creativity and tolerance to regression. Arch Gen Psychiatry. 1967;16(6):740–749. PubMed CrossRef
124. Wikler A, Haertzen CA, Chessick RD, et al. Reaction time (“mental set”) in control and chronic schizophrenic subjects and in postaddicts under placebo, LSD-25, morphine, pentobarbital and amphetamine. Psychopharmacology (Berl). 1965;7(6):423–443. PubMed CrossRef
125. Pokorny T, Preller KH, Kometer M, et al. Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol. 2017;20(9):747–757. PubMed CrossRef
126. Middlefell R. The effects of LSD on body sway suggestibility in a group of hospital patients. Br J Psychiatry. 1967;113(496):277–280. PubMed CrossRef
127. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268–283, discussion 284–292. PubMed CrossRef
128. Schmidt A, Kometer M, Bachmann R, et al. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl). 2013;225(1):227–239. PubMed CrossRef
129. Pasquini L, Palhano-Fontes F, Araujo DB. Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. J Psychopharmacol. 2020;34(6):623–635. PubMed CrossRef
130. Denson R, Sydiaha D. A controlled study of LSD treatment in alcoholism and neurosis. Br J Psychiatry. 1970;116(533):443–445. PubMed CrossRef
131. Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. Am J Psychiatry. 1969;125(10):1352–1357. PubMed CrossRef
132. Lewis CR, Preller KH, Kraehenmann R, et al. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage. 2017;159:70–78. PubMed CrossRef
133. Mason NL, Kuypers KPC, Müller F, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. 2020;45(12):2003–2011. PubMed CrossRef
134. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. Arch Gen Psychiatry. 1973;28(6):808–814. PubMed CrossRef
135. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49–69. PubMed CrossRef
136. Ditman KS, Moss T, Forgy EW, et al. Dimensions of LSD, methylphenidate and chlordiazepoxide experiences. Psychopharmacology (Berl). 1969;14(1):1–11. PubMed CrossRef
137. Haertzen CA. Changes in correlation between responses to items of the Addiction Research Center Inventory produced by LSD-25. J Psychopharmacol. 1966;1(1):27–36.
138. Robinson JT, Davies LS, Sack EL, et al. A controlled trial of abreaction with lysergic acid diethylamide (LSD-25). Br J Psychiatry. 1963;109(458):46–53. PubMed CrossRef
139. Spitzer M, Thimm M, Hermle L, et al. Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry. 1996;39(12):1055–1057. PubMed CrossRef
140. Holze F, Vizeli P, Ley L, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021;46(3):537–544. PubMed CrossRef
141. Holze F, Gasser P, Müller F, et al. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled Phase II study. Biol Psychiatry. 2023;93(3):215–223. PubMed CrossRef
142. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953–962. PubMed CrossRef
143. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620. PubMed CrossRef
144. Reissig CJ, Carter LP, Johnson MW, et al. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology (Berl). 2012;223(1):1–15. PubMed CrossRef
145. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637–1648. PubMed CrossRef
146. Furukawa TA, Noma H, Caldwell DM, et al. Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand. 2014;130(3):181–192. PubMed CrossRef
147. Başoğlu M, Marks I, Livanou M, et al. Double-blindness procedures, rater blindness, and ratings of outcome: observations from a controlled trial. Arch Gen Psychiatry. 1997;54(8):744–748. PubMed CrossRef
148. Rickels K, Lipman RS, Fisher S, et al. Is a double-blind clinical trial really double-blind? a report of doctors’ medication guesses. Psychopharmacology (Berl). 1970;16(4):329–336. PubMed CrossRef
149. Brownell KD, Stunkard AJ. The double-blind in danger: untoward consequences of informed consent. Am J Psychiatry. 1982;139(11):1487–1489. PubMed
150. Warner J, Metcalfe C, King M. Evaluating the use of benzodiazepines following recent bereavement. Br J Psychiatry. 2001;178(1):36–41. PubMed CrossRef
151. Himle JA, Abelson JL, Haghightgou H, et al. Effect of alcohol on social phobic anxiety. Am J Psychiatry. 1999;156(8):1237–1243. PubMed CrossRef
152. Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. JAMA. 1998;280(18):1590–1595. PubMed CrossRef
153. Fergusson D, Glass KC, Waring D, et al. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ. 2004;328(7437):432. PubMed CrossRef
154. Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. PubMed CrossRef
155. Johns RG, Barkham M, Kellett S, et al. A systematic review of therapist effects: a critical narrative update and refinement to review. Clin Psychol Rev. 2019;67:78–93. PubMed CrossRef
156. Hayes JA, McAleavey AA, Castonguay LG, et al. Psychotherapists’ outcomes with White and racial/ethnic minority clients: first, the good news. J Couns Psychol. 2016;63(3):261–268. PubMed CrossRef
157. Jones BDM, Razza LB, Weissman CR, et al. Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(9):e2125531. PubMed CrossRef
158. Devilly GJ, Borkovec TD. Psychometric properties of the Credibility/Expectancy Questionnaire. J Behav Ther Exp Psychiatry. 2000;31(2):73–86. PubMed CrossRef
159. Mathew SJ, Wilkinson ST, Altinay M, et al. ELEctroconvulsive therapy (ECT) vs ketamine in patients with treatment-resistant depression: the ELEKT-D study protocol. Contemp Clin Trials. 2019;77:19–26. PubMed CrossRef
160. Aday JS, Heifets BD, Pratscher SD, et al. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl). 2022;239(6):1989–2010. PubMed CrossRef